These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25265018)

  • 1. Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.
    Gan L; Jia R; Zhou L; Guo J; Fan M
    PLoS One; 2014; 9(9):e108892. PubMed ID: 25265018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
    Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
    Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
    Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A
    Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
    Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
    Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16 mutant E6/E7 construct is protective in mouse model.
    Goodarzi MM; Mosayebi G; Ganji A; Raoufi E; Sadelaji S; Babaei S; Abtahi H
    BMC Biotechnol; 2024 Sep; 24(1):71. PubMed ID: 39350162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
    Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
    Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
    Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
    Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
    Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
    Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.
    Shin TH; Pankhong P; Yan J; Khan AS; Sardesai NY; Weiner DB
    Hum Vaccin Immunother; 2012 Apr; 8(4):470-8. PubMed ID: 22336879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).
    Almajhdi FN; Senger T; Amer HM; Gissmann L; Öhlschläger P
    PLoS One; 2014; 9(11):e113461. PubMed ID: 25422946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
    Schmidt S; Bonilla WV; Reiter A; Stemeseder F; Kleissner T; Oeler D; Berka U; El-Gazzar A; Kiefmann B; Schulha SC; Raguz J; Habbeddine M; Scheinost M; Qing X; Lauterbach H; Matushansky I; Pinschewer DD; Orlinger KK
    Oncoimmunology; 2020 Sep; 9(1):1809960. PubMed ID: 33457095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.